A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology

被引:12
|
作者
Park, Kyungsoo [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pharmacol, 50-1 Yonsei Ro, Seoul 03722, South Korea
关键词
Model-based approaches; drug development; drug treatment; chemotherapeutic drug; PROGRESSION-FREE SURVIVAL; SURROGATE END-POINT; PHARMACODYNAMIC MODEL; TUMOR-GROWTH; DISEASE PROGRESSION; CANCER-PATIENTS; CHEMOTHERAPY; SIZE; TIME; PHARMACOKINETICS;
D O I
10.3349/ymj.2017.58.1.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Model-based approaches have emerged as important tools for quantitatively understanding temporal relationships between drug dose, concentration, and effect over the course of treatment, and have now become central to optimal drug development and tailored drug treatment. In oncology, the therapeutic index of a chemotherapeutic drug is typically narrow and a full dose-response relationship is not available, often because of treatment failure. Noting the benefits of model-based approaches and the low therapeutic index of oncology drugs, in recent years, modeling approaches have been increasingly used to streamline oncologic drug development through early identification and quantification of dose-response relationships. With this background, this report reviews publications that used model-based approaches to evaluate drug treatment outcome variables in oncology therapeutics, ranging from tumor size dynamics to tumor/biomarker time courses and survival response.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [31] ADMET modeling approaches in drug discovery
    Ferreira, Leonardo L. G.
    Andricopulo, Adriano D.
    DRUG DISCOVERY TODAY, 2019, 24 (05) : 1157 - 1165
  • [32] Computational approaches to modeling drug transporters
    Chang, C
    Swaan, PW
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 27 (05) : 411 - 424
  • [33] The Role of the US Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology
    McKee, Amy E.
    Farrell, Ann T.
    Pazdur, Richard
    Woodcock, Janet
    ONCOLOGIST, 2010, 15 : 13 - 18
  • [34] Comparison of different approaches to predict metabolic drug-drug interactions
    Einolf, H. J.
    XENOBIOTICA, 2007, 37 (10-11) : 1257 - 1294
  • [35] Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
    Lauren A. Marcath
    Taylor D. Coe
    Emily K. Hoylman
    Bruce G. Redman
    Daniel L. Hertz
    BMC Cancer, 18
  • [36] Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
    Marcath, Lauren A.
    Coe, Taylor D.
    Hoylman, Emily K.
    Redman, Bruce G.
    Hertz, Daniel L.
    BMC CANCER, 2018, 18
  • [37] Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches
    Sangana, Ramachandra
    Gu, Helen
    Chun, Dung Yu
    Einolf, Heidi J.
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (01) : 26 - 32
  • [38] Novel approaches to predict drug induced liver injury
    Park, B. Kevin
    DRUG METABOLISM REVIEWS, 2011, 43 : 27 - 28
  • [39] Approaches to predict drug-induced liver injury
    Yokoi, Tsuyoshi
    DRUG METABOLISM REVIEWS, 2011, 43 : 13 - 14
  • [40] Drug-drug interactions in oncology - prevalence and clinical relevance
    Hinnerkort, A.
    Liekweg, A.
    Muellerleile, U.
    Tiede, S.
    Bruellke, N.
    Jaehde, U.
    ONKOLOGIE, 2010, 33 : 1 - 1